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Autologous Transplantation for Hodgkin disease: A Tale
of Two Eras
Phillip M. Garﬁn 1, Sandra Luna-Fineman 1, Michael Amylon 2,
Sandhya Kharbanda 3, Kenneth I. Weinberg 4,
Jennifer Reikes Willert 5, Matthew Porteus 6, Michael Link 1,
Rajni Agarwal 7. 1 Pediatrics, Stanford University, Palo Alto, CA;
2 Dept. of Pediatrics, Stanford University Medical Center,
Stanford, CA; 3 Pediatric Stem Cell Transplant, Stanford
University, Palo Alto, CA; 4 Stanford University School of
Medicine, Palo Alto, CA; 5 Pediatric Hematology/Oncology/BMT,
Rady Children's Hospital/Ucsd, San Diego, CA; 6 Stanford
University; 7 Pediatric Stem Cell Transplantation, Stanford
University, Palo Alto, CA
Purpose: We evaluated outcomes for pediatric patients who
underwent autologous hematopoietic stem-cell trans-
plantation (AHSCT) for refractory or recurrent Hodgkin
Disease (HD) to identify factors that contribute to the success
or failure of their treatment.
Patients and Methods: From 1988 to 2012, 89 patients <21
years with relapsed or refractory HD underwent high-dose
therapy followed by AHSCT according to one of several
autologous transplantation protocols at Stanford University
Medical Center (Stanford, CA). Pretreatment factors were
analyzed by univariate and multivariate analysis for prog-
nostic signiﬁcance for 5-year overall survival (5 yr OS).
Results: The majority of the patients received a BCNU, eto-
poside, and cyclophosphamide conditioning regimen. The 5
yr OS in these patients was greater than that of recipients of
either other chemotherapy-only preparative (e.g. CCNU, eto-
poside, cyclophosphamide or gemcitabine, vinorelbine, eto-
poside, cyclophosphamide) or radiation-containing regimens
(75%, 61%, 50% respectively; P ¼ .0057). AHSCT at or before
second relapse resulted in better 5 yr OS than AHSCT later in
the disease course (73% v 51%, P ¼ .4). Patients who under-
went AHSCT in 2002 or later had signiﬁcantly better OS than
those who underwent transplantation between 1988 and
2001 (80% v 65%; P¼ .07). Those in the earlier erawere almost
twice as likely to die within 5 years (risk ratio 1.97). This
improvement in outcome is present even among patients
who received BCNU containing conditioning (82% 5 yr OS
2002-2012 vs. 71%5 yrOS1988-2001, P¼ .21, risk ratio 1.89). 5
yrOS correlatedmost stronglywith the eraof transplantation.
Most of the difference in outcome was attributable to
decreased mortality in the peri-transplant period.
Conclusion: Approximatley three-fourths of children who
underwent AHSCT for their recurrent or refractory HD can be
successfully treated with current therapy, conﬁrming the
continued efﬁcacy of this approach. Analyses of results by
treatment era suggest that supportive care during the peri-
transplant period has improved outcomes. The BCNU, eto-
poside, and cyclophosphamide regimen was at least as
effective as BEAM, and had greater OS than many published
reports about outcomes using BEAM. Since outcome was
related to disease status, pediatric patients should undergo
AHSCT prior to second relapse.
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Donor Lymphocyte Infusions in Pediatric Patients with
Malignant and Non-Malignant Diseases After Allogeneic
Bone Marrow Transplantation: A Single Center
Experience
Aharon Gefen 1,2, Myriam Weyl-Ben-Arush 1,2, Abdalla Khalil 1,
Nira Arad-Cohen 1, Iris Porat 1, Irina Zaidman 1. 1Department ofPediatric Hematology-Oncology, Rambam Medical Center,
Haifa, Israel; 2 Rappaport Faculty of Medicine, Technion-Israel
Institute of Technology, Haifa, Israel
Donor lymphocyte infusions (DLI) are used after alloge-
neic bone marrow transplantation (allo BMT) to treat and
prevent relapse in patients with leukemia, to prevent graft
rejection for non-malignant diseases, and to treat post-
transplant lymphoprolypherative disorder or viral infections.
The data in children, particularly in non-malignant diseases,
are limited and based on case reports and small series. We
describe our experience in using DLI in pediatric patients
with both malignant and non-malignant diseases after allo
BMT over a 3-year period.
From November 2009 to October 2012, 11 pediatric
patients, median age 9.5 years (range, 1.5-18.5 years), were
treatedwith 22 doses of DLI. Median follow-up duration after
DLI was 7 months (range, 2-32 months).
Six patients had hematological malignancies (3 eacute
lymphoblastic leukemia, 2 e acute myeloid leukemia, 1 e
chronic myeloid leukemia (CML)). DLI was given after salvage
chemotherapy (5 children) to treat relapse and achieve
remission status or to prevent relapse without previous
chemotherapy (1 patient). Median time between BMT and
DLI was 7 months (range, 4-18 months). Median CD3-T-cell
dose of DLI in patients with acute leukemia was 5x107/kg
(range, 1-10); a child with CML received 5 DLIs in escalating
cell doses. Four of six patients had DLI from matched unre-
lated donors, and developed severe multisystemic graft
versus host disease (GVHD).
Five children with non-malignant diseases (2 - thalas-
semia major, 2 - metabolic diseases, 1 - Immunodeﬁciency)
had progressively decreasing chimerism and received DLI to
prevent graft rejection. DLI was given 8 months (median;
range, 2-9 months) after BMT. Median dose was 1x107/kg
(range, 0.1-5). All patients hadmatched family donors (MFD).
In 4/5 children, DLI prevented full rejection. In 2/5 children,
stable mixed chimerism (25-35%) was enough to induce full
remission of their basic disease. All were alive at the end of
follow-up; none had GVHD.
Based on this experience, DLI achieved an excellent
response for the patient with CML; but was not effective for
treatment of full relapse in childrenwith acute leukemia, and
resulted in a high incidence of severe multisystemic GVHD.
DLI could be an effective and safe method to prevent graft
failure in children with non-malignant diseases after MFD.
The absence of GVHD in this group is most likely due to
family donors and reduced cell dose. Prospective studies of
DLI in children are needed.271
Bone Marrow Failure: Congenital Amegakaryocytic
Thrombocytopenia - A Case Report of Successful Matched
Unrelated Bone Marrow Transplantation in Pediatric
Twins
Julia Gourde 1, Preethi Marri 2, Shakila P. Khan 2, Paul Galardy 2,
Amulya NageswaraRao 2, Vilmarie Rodriguez 2. 1 Department of
Transplantation, Mayo Clinic, Rochester, MN; 2Department of
Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN
Congenital Amegakaryocytic Thrombocytopenia (CAMT)
is a rare inherited autosomal recessive bone marrow failure
disorder that presents with thrombocytopenia and absence
of megakaryocytes. Bleeding/bruising is typically recognized
on day 1 of life or at least within the ﬁrst month, with risk of
life threatening hemorrhage, requiring platelet transfusions
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transformation later in life. Diagnosis is conﬁrmed by the
MPLgene testing. Allogeneic stem cell transplantation
remains the only curative therapy. Due to its rarity, there are
few published reports with variable conditioning regimens
in the allogeneic setting.
We report two female identical twin siblings with
thrombocytopenia at birth (11,000 and 9,000 respectively)
and subsequent work up for persistent low platelets revealed
heterozygous R102P missense mutation on exon 3 of MPL
gene.Nophenotypic abnormalities noted andFanconi anemia
testing was negative. One of them progressed to aplastic
anemia (bone marrow cellularity< 30%, no clonal abnor-
mality) and received conditioning with Cytoxan 50mg/kg x 4
days, reduced dose of TBI at 200cGY x 1 and Campath 3mg/kg
x 4 days followed by transplant with 10/10 allele matched,
unrelated, CMV + donor bone marrow. Tacrolimus alone was
used for GVHD prophylaxis. Sister received myeloablative
conditioning using once a day Busulfan for 4 days based on
pharmacokinetics, Cytoxan 50mg/kg x 4 days, Campath 5mg/
kg x 3 days followed by a transplant with the same unrelated
bonemarrow donor. Tacrolimus andmini methotrexatewere
given on days +1, +3, +6, + 11. Both sisters tolerated the
transplant with minimal toxicity, durable engraftment, and
no acute or chronic GVHD. The ﬁrst twin is approximately 1.5
years post BMT and the second is past day 100.
Formatched unrelated donor transplant, the conditioning
regimen used may be variable based on patients’ clinical
presentation, bone marrow cellularity and presence of
comorbidities.272
Assessment of Iron Overload in Pediatric Patients With
Thalassemia Major During One Year Follow-Up After
Hematopoietic Stem Cell Transplantation Using T2* MRI
Technique
Amir Ali Hamidieh, Sirous Tayebi, Maryam Behfar,
Ahmadreza Shamshiri, Kamran Alimoghaddam,
Ardeshir Ghavamzadeh. Hematology, Oncology and Stem Cell
Transplantation Research center, Tehran University of Medical
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Background: Iron overload especially in heart and liver
cause serious complications for patients with thalassemia
major (TM) including cardiomyopathy which is the main
cause of death in TM patients. Using non-invasive methods
for follow-up, MRI basedmethods like T2*MRI technique has
been recentlymuchmore considered. This study investigates
the changes in iron overload in TM patients before and after
hematopoietic stem cell transplantation (HSCT) using T2*
MRI technique.
Methods: Patients with TM who were candidate for HSCT
enrolled. Cardiac and hepatic T2* values were measured
three times during the treatment; one before HSCT, one six
months later and the other one 12 months after HSCT. These
values were compared to each other to determine how
degree of iron overload changes during one year follow-up.
Results: Twenty-eight patients including 19 boys and 9 girls
with mean age 7.27years (range: 3.5-13) were included. The
mean SD for cardiac T2* values before and after HSCT (6 and
12 months) were 19.007.13, 18.778.25 and 21.727.80
respectively. These numbers for hepatic T2* values were
5.114.03, 3.832.48 and 3.562.69 respectively. While the
differences between cardiac T2* values during one yearfollow-up after HSCT were not statistically signiﬁcant (P-
value¼0.19), hepatic T2* values have decreased signiﬁcantly
(P-value¼0.001) meaning that although cardiac iron over-
load has not changed dramatically, hepatic iron overload is
getting worse even one year after HSCT.
Conclusion: Using T2* MRI for measuring iron overload in
TM patients shows that despite of receiving chelation
therapy or phlebotomy after HSCT, hepatic iron overload is
still getting worse in TM patients whereas cardiac iron
overload is the same as before transplantation. It seems that
for better understanding of liver iron overload, follow-up
should be continued for years later.273
Immune Reconstitution & Vaccine Response After
Pediatric Allo-HSCT
Erin Elizabeth Boles, Codruta Chiuzan, Dominic Ragucci,
Michelle Hudspeth. Medical University of South Carolina,
Charleston, SC
Background: Transfer of donor immunity for vaccine
preventable diseases in allo-HSCT is limited, requiring re-
vaccination after HSCT. The CDC 2009 guidelines introduced
changes, including earlier vaccination post-HSCT with
a uniform vaccination strategy irrespective of transplant
variables. The CDC guidelines acknowledge vaccination
response varies, but signiﬁcant knowledge gaps exist
regarding factors affecting immune recovery and response to
vaccination post-HSCT. The objective of this study is to
describe predictors of immune recovery and adequate
response to vaccination 1 year post-HSCT.
Methods: We conducted a retrospective chart review of all
pediatric allo-HSCT patients transplanted between July 1,
2007 through June 30, 2012 who survived >1 year post-
transplant without relapse (N¼27). For evaluation of vaccine
response, 8 patients were excluded (5 with incomplete data/
refused vaccines, 2 with cGVHD, 1 receiving IVIG). Adequate
response to vaccination was deﬁned as a > 4-fold increase in
tetanus titers >1 month after vaccination. Wilcoxon Rank-
Sum Exact test and Kruskall-Wallis tests were used to
analyze CD4, CD8, and CD19 counts with a type 1 error rate
ﬁxed at 0.05. Exact conditional logistic regression was
utilized to analyze adequate vaccination response 1 year
post-HSCT.
Results: Overall, a statistically signiﬁcant increase in median
CD4, CD8, and CD19 counts was seen from 6 to 12 months
post-HSCT (P ¼ <0.0001, 0.005, 0.004). Patients with aGVHD
or cGVHD, however, lacked a signiﬁcant increase in cell
counts. Among graft sources, CBU recipients had the highest
median cell counts. Among preparative regimens, patients
with RIC had the lowest median cell counts. Only 36% of
patients had adequate vaccination response at 1 yr post-
HSCT. For the remaining evaluable patients, 88% required one
and 12% required two additional re-vaccination attempts.
None of the variables tested (graft source, preparative
regimen, disease status, ATG/alemtuzumab, GVHD prophy-
laxis, cell counts, GVHD) were statistically signiﬁcant in
predicting adequate vaccine response.
Conclusions: There was no association between predictors
of immune recovery or transplant variables and vaccination
response in this study. A uniform vaccination strategy is
unlikely to provide protective antibodies formany post-HSCT
patients and should be evaluated in larger studies.
